橡皮鱼
Lv5
1530 积分
2022-10-22 加入
-
Safety of Immunotherapy Rechallenge After Immune-related Adverse Events in Patients With Advanced Cancer
23小时前
待确认
-
Efficacy of PD-1/PD-L1 Plus CTLA-4 Inhibitors in Solid Tumors Based on Clinical Characteristics: a Meta-Analysis
9天前
已完结
-
Efficacy of PD-1/PD-L1 Plus CTLA-4 Inhibitors in Solid Tumors Based on Clinical Characteristics: a Meta-Analysis
9天前
已关闭
-
Disease Etiology and Outcomes After Atezolizumab Plus Bevacizumab in Hepatocellular Carcinoma: Post-Hoc Analysis of IMbrave150
14天前
已完结
-
Nivolumab versus sorafenib in advanced hepatocellular carcinoma (CheckMate 459): a randomised, multicentre, open-label, phase 3 trial
14天前
已完结
-
Opportunities and challenges for MRD assessment in the clinical management of multiple myeloma
1个月前
已完结
-
Isatuximab, Carfilzomib, Lenalidomide, and Dexamethasone Induction in Newly Diagnosed Myeloma: Analysis of the MIDAS Trial
1个月前
已完结
-
Daratumumab, Carfilzomib, Lenalidomide, and Dexamethasone With Minimal Residual Disease Response-Adapted Therapy in Newly Diagnosed Multiple Myeloma
1个月前
已完结
-
Belantamab Mafodotin, Bortezomib, and Dexamethasone for Multiple Myeloma
1个月前
已完结
-
Nivolumab versus sorafenib in advanced hepatocellular carcinoma (CheckMate 459): a randomised, multicentre, open-label, phase 3 trial
1个月前
已完结